Unknown PHASE2 INTERVENTIONAL NCT00139373

Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy

Sponsor: Groupe Hospitalier Pitie-Salpetriere

Conditions Supranuclear Palsy, Progressive

Interventions donepezil

Updated 5 times since 2017 Last updated: Sep 12, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00139373, this PHASE2 trial focuses on Supranuclear Palsy, Progressive and remains ongoing. Sponsored by Groupe Hospitalier Pitie-Salpetriere, it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France

Data source: Groupe Hospitalier Pitie-Salpetriere

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France